Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Prognosis 15
3.3 Quality of Life 15
3.4 Symptoms 16
4 Disease Management 17
4.1 Diagnosis Overview 17
4.1.1 SLE Diagnosis 17
4.1.2 LN Diagnosis 20
4.2 Treatment Overview 22
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Unmet Needs 29
6.2.1 Efficacious Treatments with Reduced Side Effects 29
6.2.2 Management of LN 31
6.2.3 Improvement in Patients’ Mortality 32
6.2.4 Management of Lupus Comorbidities 32
6.2.5 Sensitive and Reliable Biomarkers 33
6.2.6 Physicians’ Education and Public Awareness of SLE 34
6.2.7 Unmet Needs Gap Analysis 34
6.3 Opportunities 35
6.3.1 Efficacious and Safe Therapies 35
6.3.2 Therapies Targeting LN Patients 36
6.3.3 Treatments for Common Lupus Comorbidities 37
6.3.4 Discovery of Biomarkers 37
7 Pipeline Assessment 38
7.1 Overview 38
7.2 Promising Drugs in Clinical Development 39
8 Blisibimod 42
8.1 Overview 42
8.2 Efficacy 43
8.3 Safety 45
8.4 Dosing and Formulation 45
8.5 Potential Clinical Positioning 45
8.6 Potential Commercial Positioning 46
8.7 Pricing and Reimbursement 46
8.8 SWOT Analysis 47
8.9 Forecast 47
9 Appendix 50
9.1 Bibliography 50
9.2 Abbreviations 52
9.3 Methodology 55
9.4 Forecasting Methodology 55
9.4.1 Diagnosed SLE and LN Patients 55
9.4.2 Percent Drug-Treated Patients 56
9.4.3 Drugs Included in Each Therapeutic Class 56
9.4.4 General Pricing Assumptions 56
9.4.5 Generic Erosion 57
9.4.6 Pricing of Pipeline Agents 57
9.5 Physicians and Specialists Included in this Study 58
9.6 Primary Research – Prescriber Survey 59
9.7 About the Authors 60
9.7.1 Analysts 60
9.7.2 Global Head of Healthcare 61
9.8 About GlobalData 62
9.9 Disclaimer 62